


# PROGRESS



**SARCOMA**  
**FOUNDATION**  
of AMERICA

# WITH PURPOSE

## TABLE OF CONTENTS

- 03 Message from the CEO
- 04 About SFA
- 06 Research
- 08 Education, Engagement, Advocacy
- 10 Events
- 12 Awareness & Outreach: Expanding Our Reach
- 14 Financials

## DEAR FRIENDS

As I reflect on 2024, I'm filled with deep gratitude and a powerful sense of what's possible when a community comes together with purpose. This year was defined not just by progress, but by people. Every step forward we've taken in research, advocacy, education, and awareness has only been possible because of you.

After listening closely to patients, caregivers, researchers, and partners, we refreshed our mission and strategic goals. These updates focus our work on real, urgent gaps in sarcoma care including earlier diagnosis, better treatment, stronger education, greater access to expert care, and targeted public policy.

To support this refresh, we also underwent a bold transformation with a new website and logo. More than just design updates, these changes represent who we are, what we stand for, and where we're headed. SFA envisions a future where no one loses their life to sarcoma.

**Research** remains at the heart of everything we do. We continued to fund grants globally, with the goal of accelerating scientific discovery and improving outcomes for patients. Our commitment to research remains our strongest path forward, and the clearest route to lasting impact.

We also leaned into **education and engagement** in new ways. Our 2024 webinar series addressed topics ranging from sub-type-specific sessions on liposarcoma and desmoid tumors to discussions about the sarcoma patient journey. Thousands tuned in, and what we heard back was clear: this kind of information empowers people to make informed decisions with confidence.

**Advocacy** took on new energy this year. One of the moments I'm most proud of was our Sarcoma Community Advocacy Day. I stood side by side with sarcoma patients, survivors, families, and advocates as we met with lawmakers to share our stories and advocate for the needs of our community. Public policy can, and must, do better for sarcoma patients.

Our efforts to raise **awareness** were equally powerful. Sarcoma Awareness Month in July featured a refreshed **Wear Yellow Day**, a nationwide social media campaign, and landmarks across the country lit up in yellow for our **Light Up for Sarcoma** initiative. We also participated in national awareness movements to ensure sarcoma stays part of the national conversation all year long.

We continued to lift the voices of those impacted by a sarcoma diagnosis. Our **Sarcoma Stories** podcast gives patients, care partners, and survivors a platform to share their experiences and change how we understand this disease. These conversations have now reached listeners in 28 countries and counting, and are inspiring advocacy, shaping research, and building a global community grounded in empathy and strength.

We also introduced the **Sarcoma Diagnosis Discussion Guide**. This impactful tool created with patient input helps individuals feel more prepared and supported when they first hear the word "sarcoma."

Our **fundraising efforts** were nothing short of extraordinary. The Race to Cure Sarcoma series kicked off in April and continued throughout the year with events in 18 cities across the country.

Over 6,200 participants came together to raise over \$1.1 million for research and patient programs. Local events, from walks to golf outings to cornhole tournaments, showed the creativity and passion of our sarcoma community. Our annual Stand Up to Sarcoma Gala in New York City was a night to remember, raising over \$500,000 and honoring some of the most inspiring individuals I've had the privilege to meet.

When I reflect on what SFA accomplished this year, I think about the people and stories behind the numbers and events. I hear the patients sharing their sarcoma journeys; I see the families honoring loved ones; the researchers pushing boundaries through action; and I am grateful for the countless supporters who showed up in ways both big and small.

You are the reason SFA is building momentum. You are the reason I believe, now more than ever, that we're moving closer to a world without sarcoma.

With heartfelt thanks,



**BRANDI FELSER**  
Chief Executive Officer  
Sarcoma Foundation of America

## MISSION STATEMENT

SFA'S MISSION IS TO IMPROVE OUTCOMES FOR PEOPLE DIAGNOSED WITH SARCOMA TO INCREASE THE NUMBER OF SURVIVORS. WE DO THIS BY FUNDING AND ADVANCING RESEARCH, EDUCATING AND PROVIDING RESOURCES FOR PEOPLE DIAGNOSED WITH SARCOMA, ADVOCATING ON BEHALF OF THE COMMUNITY, BRINGING TOGETHER THE COLLECTIVE SARCOMA VOICE, AND GROWING AWARENESS ABOUT THE DISEASE.

AS THE LARGEST AND MOST VISIBLE SARCOMA ORGANIZATION, SFA IS THE FIRST LINE RESOURCE FOR ALL THINGS SARCOMA.



### BOARD OF DIRECTORS

Mark Thornton, MD, MPH, PhD  
*President*

John Brooks, MD  
*Vice President of Scientific  
and Government Affairs*

Patricia Thornton  
*Treasurer*

Jennifer Goodwin, MBA  
*Secretary*

Michael Barron  
Chris Connery  
Justin Green  
Michael Lewis  
Bruce I. March  
Jennifer Nellany



## RESEARCH

At SFA, we believe the path to a cure for sarcoma begins with research. It is the heart of who we are and what we do. This year, we deepened our commitment to scientific discovery by funding innovative research, supporting the next generation of sarcoma investigators, and driving collaboration globally.

### STRATEGIC RESEARCH INVESTMENT

In 2024, SFA awarded over \$1 million in research grants to studies focused on sarcoma biology, immunotherapy, genomics, and targeted treatments. Our rigorous, peer-reviewed grantmaking process ensures we fund the most promising science with the greatest potential to transform patient outcomes. We are proud to support researchers globally, because sarcoma knows no borders, and neither should the search for more effective and less toxic treatments.



# EDUCATION, ENGAGEMENT, ADVOCACY

We are committed to providing the sarcoma community with knowledge, resources, and opportunities to learn and connect. Through educational programming, strategic partnerships, and policy advocacy, SFA is focused on empowering patients and amplifying their voices where it matters most.



## EDUCATION

This year, SFA expanded our educational offerings to meet the growing demand for accessible, expert-led programming. Through our **Education Series**, we hosted four live webinars on timely and high-interest topics:

- **Sarcoma Subtype Series: Liposarcoma**
- **Sarcoma Subtype Series: Desmoid Tumors**
- **ASCO Review**
- **The Sarcoma Journey**

These sessions featured leading sarcoma researchers and clinicians and drew **hundreds of registrants per webinar**, with thousands more accessing the content on-demand through our website.

## ENGAGEMENT

In 2024, SFA deepened relationships with thought leaders, clinicians, researchers, and partners across the sarcoma and cancer landscape. Our team attended or exhibited at key medical and scientific conferences, including:

- **European Society of Medical Oncology Sarcoma and Rare Cancers Congress**
- **American Society of Clinical Oncology (ASCO)**
- **ACCC Annual Meeting**
- **ASCO Quality Care Symposium**
- **Connective Tissue Oncology Society (CTOS) Annual Meeting**

These engagements help SFA stay at the forefront of scientific advances and ensure that patient needs remain a focus within the broader research and care communities.

Additionally, we expanded collaboration with industry and academic partners, positioning SFA as a trusted bridge between patient communities and sarcoma innovation.

## ADVOCACY

SFA remained a vocal advocate in 2024, ensuring that sarcoma patients and families were represented in federal policy discussions.

A major milestone this year was **SFA's Advocacy Day** in Washington, D.C. Sarcoma advocates, patients and survivors joined SFA staff to meet directly with legislators and share their personal experiences, putting a powerful, human face on the issues facing our community. Together, we highlighted critical needs such as:

- Increased federal funding for sarcoma research
- Greater support for clinical trial participation
- The importance of preserving and expanding access to telehealth, particularly for patients who live far from major cancer centers or specialized care

These conversations helped educate policymakers about the unique barriers to care that can directly impact outcomes for those affected by sarcoma. Our presence in the advocacy space reflects our commitment to empower sarcoma patients, knowing that their voices and stories drive real change.



# EVENTS

## RACE TO CURE SARCOMA

SFA supporters were off to the races with the 2024 *Race to Cure Sarcoma (RTCS)* series. The season officially kicked off in April in Atlanta, GA, and continued throughout the year with events in 18 cities across the country.

This year, more than 6,200 participants came together to raise over \$1.1 million in support of sarcoma research and to increase awareness of this disease. Each race served as a powerful platform to honor loved ones, celebrate survivors, and unite communities in a shared commitment to progress.

With every step, the RTCS community helped bring greater attention and critical resources to those affected by sarcoma.



## STAND UP TO SARCOMA GALA

In October, the sarcoma community came together for the 22nd annual *Stand Up to Sarcoma Gala* at the elegant 583 Park Avenue in New York City. The evening delighted guests with inspiring entertainment, a lively auction, and a moving recognition program, while raising over **\$500,000** to advance our mission.

The event honored the below leaders and changemakers in the sarcoma space:

- **The Amira Yunis Courage Award** was presented to sarcoma patient **Sean Cincotta** of Pennsylvania for raising awareness and supporting research through the Race to Cure Sarcoma Philadelphia.
- **The Nobility in Science Award** honored **Cristina R. Antonescu, MD** of Memorial Sloan Kettering Cancer Center for her groundbreaking contributions to sarcoma research.
- **The Compassionate Care Award** was given to **Jaclyn Cardarelli-Matte, LICSW** of Massachusetts General Hospital for her dedication to patient-centered care.
- **The Vision of Hope Award** recognized **David Fajgenbaum, MD, MBA, MSc** of the University of Pennsylvania for his work transforming rare disease research and treatment.
- **The Courage Award** celebrated the strength and achievements of Paralympians **Emily Oberst, Nate Hinze, and Kelly Elmlinger**. These athletes use their platforms to raise awareness and inspire and bring hope to those diagnosed with sarcoma each year.

The gala was a powerful reminder of what we can accomplish together, honoring those who lead with purpose while raising critical funds to improve outcomes for those affected by sarcoma.

## PATIENTS AND FAMILIES SUPPORTING CANCER RESEARCH


We are continually inspired by the passionate members of the sarcoma community who step forward to organize events that raise awareness and critical funds for research. In 2024, supporters across the country found meaningful and creative ways to raise dollars and build momentum for SFA. Fundraisers included music concerts, golf outings, community walks, and 10K runs.

Each event, whether large or small, was a testament to the power of individuals rallying for SFA's cause. We are honored to be the organization so many in the sarcoma community choose to support, and we remain deeply grateful for the energy and heart behind every fundraiser.



## AWARENESS & OUTREACH: EXPANDING OUR REACH

SFA significantly expanded its outreach efforts to raise awareness about sarcoma and strengthen connections within the broader cancer community.



**Sarcoma Awareness Month** in July remained the centerpiece of our awareness efforts. The month featured SFA's **Wear Yellow Day** and **Light Up for Sarcoma** as well as a coordinated campaign that included a robust social media strategy and custom graphics designed to engage supporters and raise visibility globally. These combined efforts not only educated the public but also empowered our community to share their stories and demonstrate solidarity.

Throughout the year, SFA also acknowledged important cancer-related observances through social media, website graphics, and public communications. These included **National Childhood Cancer Awareness Month**, **National Cancer Research Month**, and **AYA (Adolescent and Young Adult) Cancer Awareness Week**, as well as other recognition days and months that spotlight the unique challenges that affect rare cancer patients. These activities reflected SFA's continued commitment to education and advocacy on behalf of all those impacted by sarcoma.

### NEW WEBSITE AND LOGO: A FRESH LOOK FOR A BOLD VISION

To support our refreshed mission and strategic goals, SFA unveiled a redesigned website and a new logo in 2024. These updates symbolize who we are, what we stand for, and our commitment to a future where no one loses their life to sarcoma.

Our new digital presence is designed to make information and resources more accessible and advocacy efforts more effective. Together, these changes are a clear, outward expression of our dedication to lasting change in the sarcoma community.



### EXPANDING PATIENT RESOURCES AND TOOLS

This year, SFA introduced the **Sarcoma Diagnosis Discussion Guide**. Developed with direct input from sarcoma patients, this impactful resource is designed to support patients and their care partners during diagnosis, which can be one of the most critical moments in the sarcoma journey. By encouraging self-advocacy and offering practical guidance, the Sarcoma Diagnosis Discussion Guide helps patients navigate complex discussions with their healthcare providers. This tool is a starting point for informed, empowered decision-making.


### SARCOMA STORIES PODCAST

Another groundbreaking initiative at SFA is **Sarcoma Stories**. Sarcoma Stories is a podcast created to fill a void in the cancer podcast landscape where expert voices are common, but the lived experiences of those directly impacted are often missing.

This innovative podcast provides a platform for connection, community, and education by amplifying personal stories from patients, survivors, caregivers, and advocates. These powerful conversations have now reached listeners in 28 countries and growing.

The impact of Sarcoma Stories doesn't end when the recording stops. Guest stories have sparked ongoing conversations, inspired others to share their experiences, and motivated some to train as research advocates. Sarcoma patients are now shaping research design and advocacy strategies, underscoring how storytelling and community drives real change.

# FINANCIALS



## FUNCTIONAL EXPENSES

PROGRAM	\$ 2,735,273 (72.5%)
MGMT AND GENERAL	495,779 (13.1%)
FUNDRAISING	541,331 (14.4%)
<b>TOTAL</b>	<b>\$ 3,772,383</b>

## ASSETS

Current Assets	
Cash and Cash Equivalents	\$ 2,661,896
Contributions Receivable	124,126
Investments	8,392,537
Prepaid Expenses	60,725
Fixed Assets, Net	74,983
Operating Right-of-Use Asset	87,227
Other Assets	21,634

**TOTAL ASSETS \$ 11,423,128**

## LIABILITIES

Current Liabilities	
Accounts Payable and Accrued Expenses	\$ 223,287
Operating Lease Liability	108,486
Grants payable	57,035

**TOTAL LIABILITIES \$ 348,378**

## NET ASSETS

Without Donor Restrictions	8,954,255
With Donor Restrictions	
Purpose Restricted	1,768,187
Endowment	301,878

**TOTAL NET ASSETS WITH DONOR RESTRICTIONS 9,266,426**

**TOTAL NET ASSETS 9,266,426**

**TOTAL LIABILITIES AND NET ASSETS \$ 9,805,602**

## REVENUES

	WITHOUT DONOR RESTRICTIONS	WITH DONOR RESTRICTIONS	TOTAL
Contributions	\$ 1,794,423	\$ 400,000	\$ 2,194,423
Donated Services	56,125		56,125
Special Events	1,499,968		1,499,968
Less Costs of Direct Benefits to Donors	(438,667)		(438,667)
Other Income	29,727		29,727
Net Assets Released from Restrictions	357,153	(357,153)	

**TOTAL REVENUE 3,298,729 42,847 2,802,321**

## EXPENSES

Program Services	2,735,273		2,735,273
Management and General	495,779		495,779
Fundraising	541,331		541,331

**TOTAL EXPENSES 3,772,383 3,772,383**

Change in Net Assets from Operations (473,654) 42,847 (430,807)

Nonoperating Activities  
Net Investment Income 873,180 76,434 949,614

Change in Net Assets 399,526 119,281 518,807

Net Assets, Beginning of Year 8,554,729 1,950,784 10,505,513

**NET ASSETS, END OF YEAR \$ 7,369,811 \$ 2,070,065 \$ 11,024,320**

# 2024 AR



7700 Wisconsin Avenue, Suite 310  
Bethesda, MD 20814  
[curesarcoma.org](http://curesarcoma.org)